Document:

Exhibit 10.2

 

March 7, 2019

 

Shore Suven Pharma, Inc.

1100 Cornwall Road, Suite 110

Monmouth Junction, New Jersey 08852

 

Re:         Equity Commitment
Letter

 

Ladies and Gentlemen:

 

Suven Life Sciences Limited, an entity organized under the laws of India (including its successors and assigns, “Suven”), Vimal Kavuru,
individually (“Kavuru”), Shore Pharma Investments, LLC, a Delaware limited liability company (“Shore”)
and Casper Pharma Private Limited (“Casper” and together with Suven, Kavuru and Shore, each an “Investor”
and together, the “Investors”), jointly and severally, are pleased to offer this commitment, on the terms and
subject to the conditions contained herein, to purchase, directly or indirectly, equity interests in Shore Suven Pharma, Inc.,
a Delaware corporation (“Buyer”). It is contemplated that, subject and pursuant to the terms of that certain
Asset Purchase Agreement, of even date herewith, by and among Buyer, Rising Pharmaceuticals, Inc., a Delaware corporation (“Rising”),
PACK Pharmaceuticals, LLC, an Arizona limited liability company, Rising Health, LLC, a Delaware limited liability company, and
Acetris Health, LLC, a Delaware limited liability company (collectively with Rising, the “Sellers” and each,
a “Seller”), and Aceto Corporation, a New York corporation (as the same may be amended, restated, supplemented
or otherwise modified from time to time in accordance with its terms, the “Purchase Agreement”), Buyer will
purchase the Purchased Assets and assume the Assumed Liabilities from Sellers. Capitalized terms used but not otherwise defined
herein have the meanings ascribed to such terms in the Purchase Agreement.

 

1.           Commitment.
   The Investors hereby agree to contribute, or cause to be contributed, as a contribution to Buyer, an aggregate amount in cash equal
to $137,250,000 (the “Contribution”) no later than the Closing, minus the amounts actually and irrevocably contributed
by each of Suven, Kavuru, Shore and Casper, in accordance with the terms hereof. Each of Suven, Kavuru, Shore and Casper irrevocably
agrees that the obligation of each of them to pay the Contribution hereunder shall be joint and several among them, provided
that it is understood that none of the Investors, individually, shall be obligated or liable hereunder for more than the Contribution.
The proceeds of the Contribution shall be used by Buyer, to the extent necessary, solely to fund (i) the Purchase Price, (ii) the
Cure Costs and (iii) related costs, fees and expenses required to be paid by the Buyer (or each Investor) at Closing in connection
with the transactions contemplated by the Purchase Agreement, in each case of clauses (i), (ii) and (iii), pursuant to and in accordance
with the terms of, and subject to the conditions of, the Purchase Agreement. The undersigned will provide additional evidence of
their financial wherewithal with respect to the full amount of the Contribution no later than seven (7) calendar days after the date hereof.
The undersigned will, no later than the Closing, have sufficient immediately available funds in lawful money of the United States
to fund the Contribution. Notwithstanding anything else to the contrary in this letter agreement, the cumulative liability of each
Investor and/or all Investors together under this letter agreement shall at no time exceed the Contribution. The amount of the
Contribution hereunder may be reduced, on a dollar-for-dollar basis, in the sole discretion of Buyer if and only if, and then only
to the extent that, Buyer does not require the full amount of the Contribution for the purpose of the payments to be made at or
in connection with the Closing as set forth in clauses (i) through (iii) above. Each Investor may allocate and/or assign all or
a portion of the Contribution to one or more of its Affiliates, and the Contribution hereunder will be reduced by any amounts actually
and irrevocably contributed to Buyer by such Affiliates (and not returned) at or prior to the Closing Date. Notwithstanding the
foregoing, each Investor agrees that any such assignment shall not relieve such Investor of its or his joint and several obligation
to fund the full amount of the Contribution until such assignee actually and irrevocably funds such assigned portion of the Contribution,
and then only to the extent of such funding.

 

    	 	 	 

     

    

 

2.            Closing
Conditions.    Each Investor’s joint and several obligation to fund the Contribution pursuant to this letter agreement is
subject to the satisfaction, prior to or contemporaneously with the Closing, of the following having occurred: (a) the satisfaction,
or express written waiver by Buyer, of all conditions precedent to the obligation of Buyer to consummate the transactions contemplated
by the Purchase Agreement set forth in Section 7.1 and Section 7.3 thereof (other than those conditions that by their nature are
to be satisfied at the Closing (but subject to all conditions being satisfied at the Closing)) as of the date of the intended Closing
pursuant to the terms of the Purchase Agreement; provided, however, that each Investor may not rely, as a basis for
not funding the Contribution, on the failure of any condition precedent to the obligation of Buyer to consummate the transactions
contemplated by the Purchase Agreement set forth in Section 7.1 and Section 7.3 thereof to be satisfied if such failure was caused
by Buyer’s material breach of any provision of the Purchase Agreement as determined by a court of competent jurisdiction;
(b) (i) the substantially contemporaneous consummation of the Asset Purchase in accordance with the terms of the Purchase Agreement
or (ii) Sellers shall have irrevocably confirmed in writing to Buyer that if the Contribution is funded, then Sellers will proceed
with their obligation to consummate the Closing pursuant to Article I of the Purchase Agreement; and (c) the Purchase Agreement
shall not have been terminated in accordance with its terms.

 

    	 	-2-	 

     

    

 

3.            Enforcement/Recourse.
   Each of Buyer and Sellers, as third party beneficiaries to the extent set forth in Section 6, shall be entitled to enforce
the joint and several obligation of each Investor to cause the Contribution to be funded or to be entitled to an injunction or
an order of specific performance (or any other non-monetary equitable remedy) to cause the Contribution (or applicable portion
thereof) to be funded in accordance with this letter agreement (for the avoidance of doubt, subject to the satisfaction of the
conditions set forth in Section 2). Notwithstanding the foregoing or anything to the contrary in this letter agreement,
Buyer shall have no right to enforce this letter agreement without the consent of each Investor in their sole discretion; provided,
however, that this sentence does not limit Sellers’ right to enforce this letter agreement in any respect. Each Investor
(A) agrees not to oppose an injunction or an order of specific performance (or any other non-monetary equitable remedy) on
the basis that Sellers have an adequate remedy at law and (B) agrees that Sellers shall not be required to post a bond or
undertaking in connection with such injunction or order or to prove actual damages. Each Investor acknowledges and agrees that
Sellers are relying on the joint and several obligations and commitments of such Investor hereunder in connection with, and such
obligations and commitments of such Investor are a material inducement to, Sellers’ decision to enter into and consummate
the transactions contemplated by the Purchase Agreement. Sellers’ (i)  rights as third party beneficiaries as set forth
in this letter agreement, (ii) remedies against Buyer and its successors or assignees under the Purchase Agreement and (iii)
remedies against each Investor under the Confidentiality Agreement, as applicable, shall, and are intended to be, the sole and
exclusive direct or indirect rights of or remedies available to Sellers and their respective Affiliates against such Investor and
any Related Person in respect of any liabilities or obligations arising under, or in connection with, this letter agreement or
the Purchase Agreement or the transactions contemplated hereby or thereby, including without limitation in the event Buyer breaches
its obligations under the Purchase Agreement, whether or not such breach is caused by such Investor’s breach of its or his
obligations under this letter agreement; provided, further, that, in the event Sellers successfully compel specific
performance of the obligations of Buyer to consummate the Asset Purchase (in accordance with, and subject to the terms and conditions
set forth in, the Purchase Agreement), and such Investor shall have made the Contribution, then neither Sellers nor any other Person
(including Sellers’ equityholders, Affiliates and Subsidiaries) shall have any remedy against such Investor or any Related
Person (other than as set forth in clauses (ii) and (iii) of this sentence), under this letter agreement. By its acceptance hereof,
Buyer acknowledges and agrees that, other than as set forth in clauses (i), (ii) and (iii) of the immediately preceding sentence
with respect to each Investor or Buyer, as applicable, (a) notwithstanding that such Investor may be a limited liability entity,
no recourse hereunder or under the Purchase Agreement may be had against any Related Person, whether by the enforcement of any
judgment or assessment or by any legal or equitable proceeding or by virtue of any statute, regulation or other applicable law,
and (b) no personal liability whatsoever will attach to, be imposed on or otherwise be incurred by Related Persons in connection
with this letter agreement or the Purchase Agreement for any claim based on, in respect of or by reason of such obligations or
by their creation. For purposes of this letter agreement, the term “Related Person” shall mean, with respect
to each Investor, and as applicable, any former, current or future director, manager, officer, employee, agent or Affiliate of
such Investor, any former, current or future direct or indirect holder of any equity interests or securities of such Investor (whether
such holder is a limited or general partner, member, manager, stockholder or otherwise), any former, current or future assignee
of such Investor or any former, current or future director, officer, employee, agent, general or limited partner, manager, member,
stockholder, Affiliate, controlling person, representative or assignee of any of the foregoing; provided that Kavuru shall
not be deemed a “Related Person” of Shore for purposes of this letter agreement.

 

    	 	-3-	 

     

    

 

4.            Expiration.
   All obligations under this letter agreement shall expire and terminate automatically and immediately upon the earlier to occur
of (a) 30 days after the valid termination of the Purchase Agreement in accordance with its terms (provided that, for the
avoidance of doubt, any purported termination of the Purchase Agreement that is not a valid termination shall not give rise to
a termination of this letter agreement pursuant to this Section 4(a)) and (b) the consummation of the Closing, including
the payment of all amounts required to be paid by Buyer in accordance with Sections 2.2, 2.3 and 2.7(a) of the Purchase Agreement.

 

5.            No
Assignment.    Neither this letter agreement nor any of the rights, interests or obligations hereunder shall be assignable by
Buyer without each Investor’s and Sellers’ prior written consent, and the granting of such consent in any given instance
shall be solely in the discretion of such Investor and Sellers, as applicable, and, if granted, shall not constitute a waiver of
this requirement as to any subsequent assignment. Neither this letter agreement, nor each Investor’s joint and several obligations
hereunder shall be assigned by such Investor without Buyer’s and Sellers’ prior written consent, and the granting of
such consent in any given instance shall be solely in the discretion of Buyer and Sellers, as applicable, and, if granted, shall
not constitute a waiver of this requirement as to any subsequent assignment; provided that such Investor may assign or allocate
all or a portion of the Contribution to one or more of its or his Affiliates as set forth in Section 1 (provided,
further, that any such assignment shall not relieve such Investor of its or his joint and several obligation to fund the
full amount of the Contribution until such assignee actually and irrevocably funds such assigned portion of the Contribution, and
then only to the extent of such irrevocable funding). Any purported assignment of this commitment in contravention of this Section
5 shall be null and void. Each Investor acknowledges that Sellers have entered into the Purchase Agreement in reliance upon,
among other things, this letter agreement and their rights and remedies hereunder, and that this letter agreement constitutes a
material inducement to Sellers’ execution and delivery of the Purchase Agreement.

 

6.            No
Other Beneficiaries.    This letter agreement shall inure to the benefit of, and be binding upon, Buyer and each Investor. Each
of Buyer and each Investor acknowledges and agrees that each Seller shall be an express third party beneficiary of, and shall be
entitled to enforce, the provisions set forth in Sections 1, 3, 4, 5, 6, 7, 8,
9, 10, 11, 12 and 13, subject to the limitations with respect thereto set forth in Section
3. Except for the third party beneficiary rights provided to Sellers under Sections 1, 3, 4, 5,
6, 7, 8, 9, 10, 11, 12 and 13, this letter agreement shall be binding on
each Investor solely for the benefit of Buyer, and nothing set forth in this letter agreement is intended to or shall confer upon
or give to any Person other than Buyer any benefits, rights or remedies under or by reason of, or any rights to enforce or cause
Buyer to enforce, the Contribution or any provisions of this letter agreement; provided that, notwithstanding anything to
the contrary in this letter agreement, any Related Person shall be a third party beneficiary of the provisions set forth herein
that are for the benefit of any Related Person (including the provisions of Sections 3, 6, 8, 9, 10
and 12), and all such provisions shall survive any termination of this letter agreement indefinitely. Without limiting the
foregoing, no creditor of Buyer shall have any right to enforce this letter agreement or to cause Buyer to enforce this letter
agreement, except that Sellers may enforce this letter agreement in accordance with Section 3 and this Section 6.

 

    	 	-4-	 

     

    

 

7.            Representations
and Warranties.    Each of Suven, Shore and Casper hereby represents, warrants and covenants as to itself that: (a) it is
duly organized, validly existing and in good standing under the Laws of the jurisdiction of its organization; (b) it has all
requisite power and authority to enter into this letter agreement and consummate the transactions contemplated hereby; (c) the
execution and delivery of this letter agreement by such Investor and the consummation by such Investor of the transactions contemplated
hereby have been duly authorized by all necessary action on the part of such Investor and no other proceedings on the part of such
Investor are necessary therefor; and (d) the execution, delivery and performance by such Investor of this letter agreement does
not and will not violate the organizational documents of such Investor. Kavuru hereby represents and warrants that he has full
power and capacity to enter into this letter agreement and consummate the transactions contemplated hereby. Each Investor hereby
further represents, warrants and covenants that: (a) this letter agreement has been duly and validly executed and delivered by
such Investor and is valid, binding, and enforceable in accordance with its terms (except as and to the extent that such validity
and enforceability may be subject to the Enforceability Exceptions); (b) the execution, delivery and performance by such Investor
of this letter agreement does not and will not violate any applicable Law, or result in any violation or breach of, or default
(with or without notice or lapse of time or both) under, or give rise to a right of termination, cancellation or acceleration of
any obligation, any contract to which such Investor is a party, except as would not prevent or materially delay such Investor’s
ability to perform its or his obligations hereunder; (c) other than as expressly contemplated in the Purchase Agreement, all approvals
of, filings with and notifications to any Governmental Authority or other Person necessary for the due execution, delivery and
performance of this letter agreement by such Investor have been obtained or made and all conditions thereof have been duly complied
with, and no other action by, and no notice or filing with, any Governmental Authority or other Person is required in connection
therewith, except as would not prevent or materially delay such Investor’s ability to perform its or his obligations hereunder;
and (d) such Investor has the ability to pay and perform (or cause to be paid or performed) its or his obligations under this
letter agreement, and access to all funds necessary for such Investor to fulfill its or his obligations under this letter agreement
shall be available to such Investor for so long as this letter agreement shall remain in effect pursuant to its or his terms (for
purposes of clarity, it is hereby acknowledged that such funds may not be in the possession of such Investor at all times but such
Investor has and shall have the ability, at all times this letter agreement is in effect pursuant to its terms, to have necessary
access (not subject to any conditions that such Investor has reason to believe would not be satisfied when the Contribution is
required to be made hereunder) to such funds, in order to effect the Closing in accordance with the terms of the Purchase Agreement).
So long as this letter agreement is in effect, each Investor hereby covenants and agrees that such Investor shall not pursue, and
shall cause each of its or his Affiliates not to pursue, directly or indirectly, any litigation or bring any other claim, asserting
that this letter agreement is illegal, invalid or unenforceable in accordance with its terms. All representations, warranties,
covenants and agreements of each Investor contained in this letter agreement shall survive the execution and delivery of this letter
agreement and shall continue in full force and effect, until the termination of this letter agreement in accordance with its terms.

 

    	 	-5-	 

     

    

 

8.            Severability.
   Any term or provision of this letter agreement which is invalid or unenforceable in any jurisdiction shall, as to that jurisdiction,
be ineffective to the sole extent of such invalidity or unenforceability without rendering invalid or unenforceable the remainder
of such term or provision or the remaining terms and provisions of this letter agreement in any jurisdiction and, if any provision
of this letter agreement is so broad as to be unenforceable, such provision shall be interpreted to be only so broad as is enforceable;
provided, however, that this letter agreement may not be enforced without giving effect to the provisions of the
fifth sentence of Section 1 and Sections 2, 3, 4, 5, 6, 9 and 10. No party
hereto shall assert, and each party hereto shall cause its or his respective Affiliates not to assert, that this letter agreement
or any part hereof is invalid, illegal or unenforceable.

 

9.            Jurisdiction.    All Proceedings arising out of or relating to this letter agreement, including
the resolution of any and all disputes hereunder, shall be heard and determined in the Bankruptcy Court, and the parties
hereto irrevocably submit to the exclusive jurisdiction of the Bankruptcy Court in any such Proceeding and irrevocably waive
the defense of an inconvenient forum to the maintenance of any such Proceeding. The parties hereto agree that service of
process may be effected in the same manner that notices may be given hereunder, notwithstanding the Law of any jurisdiction
which may prescribe specific and/or different methods of service and that nothing herein shall affect the right to effect
service of process in any other manner permitted by applicable Law.

 

10.          Waiver
of Jury Trial.    EACH OF THE PARTIES HERETO HEREBY IRREVOCABLY WAIVES ALL RIGHT TO TRIAL BY JURY IN ANY ACTION, PROCEEDING OR
COUNTERCLAIM (WHETHER BASED ON CONTRACT, TORT OR OTHERWISE) ARISING OUT OF OR RELATING TO THIS LETTER AGREEMENT OR THE ACTIONS
OF THE PARTIES HERETO IN THE NEGOTIATION, ADMINISTRATION, PERFORMANCE AND ENFORCEMENT HEREOF. EACH OF THE PARTIES HERETO MAKES
THIS WAIVER VOLUNTARILY AND SUCH PARTY HAS BEEN INDUCED TO ENTER INTO THIS LETTER AGREEMENT BY, AMONG OTHER THINGS, THE MUTUAL
WAIVERS CONTAINED IN THIS SECTION 10.

 

11.          Headings;
References.    Headings of the Sections of this letter agreement are for convenience of the parties only and shall be given no
substantive or interpretive effect whatsoever. When a reference is made in this letter agreement to a Section, such reference shall
be to a Section of this letter agreement unless otherwise indicated.

 

12.          Governing
Law; Entire Agreement; Amendment; Counterparts.    This letter agreement and the obligations hereunder shall be governed by and
construed in accordance with the Laws of the State of New York, regardless of the Laws that might otherwise govern under applicable
principles of conflicts of law thereof. This letter agreement, the Purchase Agreement and the Confidentiality Agreement constitute
the entire agreement with respect to the subject matter hereof, and supersede all other prior agreements, understandings and statements,
both written and oral, between or among Buyer or any of its Affiliates, on the one hand, and each Investor or any of its or his
Affiliates, on the other hand, with respect to the subject matter hereof. Any provision of this letter agreement may be amended
or waived if, and only if, such amendment or waiver is in writing and signed by Sellers, each Investor and Buyer. This letter agreement
may be executed in counterparts (including by facsimile or electronically transmitted signature pages), each of which shall be
an original, with the same effect as if the signatures thereto and hereto were upon the same instrument, and shall become effective
when one or more counterparts have been signed by each of the parties and delivered (by telecopy or otherwise) to the other parties.

 

    	 	-6-	 

     

    

 

13.          Notices.   
All notices and other communications hereunder shall be in writing and shall be deemed given: (a) upon personal delivery to the
party to be notified; (b) when received if sent by email or facsimile by the party to be notified; provided that notice
given by email or facsimile shall not be effective unless either (i) a duplicate copy of such email or fax notice is promptly given
by one of the other methods described in this Section 13 or (ii) the receiving party confirms receipt of such notice either
by email or fax or any other method described in this Section 13; or (c) when delivered by a courier (with confirmation
of delivery), such as Federal Express, DHL or UPS; in each case to the party to be notified at the following address:

 

if to Suven:

 

Suven Life Sciences, Limited

Registered Office: 8-2-334

SDE Serene Chambers, 6th
Floor, Road No. 5

Avenue 7

Banjara Hills

Hyderabad – 500 034

Telangana, India

 

if to Kavuru or Shore:

 

(c/o) Vimal Kavuru

[   ]

 

if to Casper:

 

Casper Pharma Private Limited

Syno 99/1 Mamidipally Village Gmr
Aviation

Sez Balapur Mandal Shamshabad Near
Novotel Hotel

Hyderabad

Telangana, India

 

And, for any such Investors, with
copy to:

 

Reed Smith LLP

599 Lexington Avenue, 22nd Floor

New York, New York 10022

Facsimile:       (212) 521-5450

Attention:       Niket Rele, Esq.

Email:             nrele@reedsmith.com

 

if to Buyer or Sellers:
as provided in Section 9.7 of the Purchase Agreement; or to such other address as such party shall specify by written notice so
given, and such notice shall be deemed to have been delivered as of the date so telecommunicated or personally delivered. Any party
to this letter agreement may notify in writing any other party of any changes to the address or any of the other details specified
in this Section 13; provided that such written notification shall only be effective on the date specified in such
notice or five (5) Business Days after the notice is given, whichever is later. Rejection or other refusal to accept or the inability
to deliver because of changed address of which no notice was given shall be deemed to be receipt of the notice as of the date of
such rejection, refusal or inability to deliver.

 

[Remainder of page intentionally left
blank]

 

    	 	-7-	 

     

    

 

	 	Very truly yours,
	 	 
	 	Suven Life Sciences, Limited
	 	 	 
	 	By:	/s/ Venkat Jasti
	 	Name:	 Venkat Jasti
	 	Title:	CEO

 

	 	Shore Pharma Investments, LLC 
	 	 
	 	By:	/s/ Vimal Kavuru
	 	Name:	Vimal Kavuru
	 	Title:	CEO
	 	 	 
	 	/s/ Vimal Kavuru
	 	Vimal Kavuru, as an individual

 

	 	Casper Pharma Private Limited
	 	 	 
	 	By:	/s/ Vimal Kavuru
	 	Name:	Vimal Kavuru
	 	Title:	CEO and Managing Member

 

[Signature Page to Equity Commitment Letter]

 

    	 	 	 

     

    

 

Agreed to and accepted as of the date first
written above:

 

	Shore Suven Pharma, Inc.	 
	 	 
	By:	/s/ Vimal Kavuru	 
	Name:	 Vimal Kavuru	 
	Title:	CEO	 

 

[Signature Page to Equity Commitment Letter]

 

    	 	 	 

     

    

 

	Rising Pharmaceuticals, Inc.	 
	 	 	 
	By:	/s/ William C. Kennally, III	 
	Name:	William C. Kennally, III	 
	Title:	Chief Executive Officer	 

 

	PACK Pharmaceuticals, LLC	 
	 	 	 
	By:	/s/ William C. Kennally, III	 
	Name:	William C. Kennally, III	 
	Title:	Chief Executive Officer	 

 

	Rising Health, LLC	 
	 	 	 
	By:	/s/ William C. Kennally, III	 
	Name:	William C. Kennally, III	 
	Title:	Chief Executive Officer	 

 

	Acetris Health, LLC	 
	 	 	 
	By:	/s/ William C. Kennally, III	 
	Name:	William C. Kennally, III	 
	Title:	Chief Executive Officer	 

 

[Signature Page to Equity Commitment Letter]Exhibit 10.3

 

MUTUAL RELEASE OF CLAIMS

 

This Mutual Release
of Claims (this “Mutual Release”) is made as of March 7, 2019, by and among (i) Aceto Corporation, a New York
corporation (“Parent”), Rising Pharmaceuticals, Inc., a Delaware corporation (“Rising”),
Acetris Health, LLC, a Delaware limited liability company (“Purchaser I”), and Rising Health, LLC, a Delaware
limited liability company (“Purchaser II” and together with Purchaser I, “Purchasers”; and
Purchasers, together with Parent and Rising , the “Parent Parties”); and (ii) Shore Pharma LLC, a New Jersey
limited liability company, Cedar Pharma LLC (f/k/a Citron Pharma LLC), a New Jersey limited liability company, Aster Pharma LLC
(f/k/a Lucid Pharma LLC), a New Jersey limited liability company, Citgen Pharma Holding LLC, a New Jersey limited liability company,
Gensource Pharma LLC, a Delaware limited liability company, SS Pharma LLC, a New Jersey limited liability company, Pharma Reach
LLC, a New Jersey limited liability company, Citgen Realty LLC, a New Jersey limited liability company, Sudha Kavuru, an individual,
Vimal Kavuru, in his capacity as an individual and in his capacity as Agent (“Kavuru”), and Subha Sri Thogarchedu,
an individual (collectively, the “Released Sellers”; and the Released Sellers collectively with the Parent Parties,
the “Parties”, and each individually, a “Party”).

 

RECITALS

 

WHEREAS, certain of
the Parent Parties and certain of the Released Sellers are parties to a Product Purchase Agreement, dated as of November 2, 2016
(as amended, the “Product Purchase Agreement”; capitalized terms used but not defined in this Mutual Release
shall have the meanings given to such terms in the Product Purchase Agreement, unless otherwise specified), pursuant to which,
among other things, such Released Sellers, directly or indirectly, sold certain assets to Purchasers, and Purchasers assumed certain
related liabilities;

 

WHEREAS, certain of
the Parent Parties, certain of the Released Sellers and certain other parties are parties to the Signing Agreements and Ancillary
Agreements (collectively with the Product Purchase Agreement, the “Transaction Agreements”), pursuant to the
terms of the Product Purchase Agreement;

 

WHEREAS, on February
19, 2019, the Parent Parties commenced voluntary petitions for relief under Chapter 11 of Title 11 of the United States Code, 11
U.S.C. §§ 101, et seq. (the “Bankruptcy Code”), in the United States Bankruptcy Court for the District
of New Jersey (the “Bankruptcy Court”), where such bankruptcy cases are administered under Case No. 19-13448
(the “Bankruptcy Case”);

 

WHEREAS, on or about
the date hereof, Rising and Purchasers (together with Rising, the “Rising Sellers”), Parent, and Shore Suven
Pharma, Inc., a Delaware corporation (the “Rising Buyer”), have entered into an Asset Purchase Agreement (the
“Rising Purchase Agreement”), pursuant to which, among other things, the Rising Sellers have agreed to sell
certain assets to the Rising Buyer, and the Rising Buyer has agreed to assume certain liabilities of the Rising Sellers (Buyer’s
consummation of such transaction pursuant to the terms and conditions set forth in the Rising Purchase Agreement or otherwise in
connection with the bankruptcy auction process, and pursuant to Section 363 of the Bankruptcy Code, the “Closing”);

 

    	 	 	 

     

    

 

WHEREAS, in addition
to the mutual releases contained herein, as consideration for (a) the Rising Buyer’s agreement that the Rising Purchase Agreement
serve as a “stalking horse” in connection with a sale pursuant to Section 363 of the Bankruptcy Code, (b) an upfront
reduction of the Deferred Payment Amount, and the interest due thereon, in the amount of $18,500,000 by the Released Sellers, which will be accounted for by way
of (i) a $500,000 reduction of the past due interest owed on the Deferred Payment Amount (the “Interest Credit”)
and (ii) a $18,000,000 reduction of the Deferred Payment Amount (the “Release-Related DPA Reduction”), and (c)
a full release of the claims against the Parent Parties as set forth in this Mutual Release, (1) the Rising Sellers will provide
the Break-Up Fee and Expense Reimbursement to the Rising Buyer in accordance with the terms described in the Rising Purchase Agreement
and (2) the Parent Parties will provide a full release of the claims against the Released Sellers as set forth in this Mutual Release;

 

WHEREAS, the Released
Sellers that are party to the Product Purchase Agreement were, or are presently, affiliates of the Rising Buyer, and the Purchasers
under the Product Purchase Agreement were, and are presently, affiliates of Rising and Parent;

 

WHEREAS, the Rising
Sellers and certain of the Released Sellers are in discussions regarding certain disputes and/or potential disputes in respect
of each of such Parties’ rights and obligations under the Product Purchase Agreement; and

 

WHEREAS, the Parties
wish to enter into this Mutual Release, to assure that, except as provided herein, all claims, demands, liabilities, damages, obligations,
actions, or causes of action of any kind between the Parties are fully and finally discharged, released, and resolved, without
any admission of wrongdoing, guilt, liability, obligation or otherwise.

 

NOW, THEREFORE, in
consideration of the foregoing and the representations, warranties, covenants and agreements contained herein, and for other good
and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, and intending to be legally bound, the
Parties hereby agree as follows:

 

		1.	Mutual Release.

 

		a.	Effective as of the Effective Date and only if the Effective Date occurs, and to the fullest extent
permitted by Law, each of the Parent Parties, on behalf of itself and any Person or entity claiming by, through or under it, including
their respective subsidiaries, affiliates, predecessors, successors, and assigns, and all of their respective directors, managers,
officers, agents, advisors, and representatives (collectively, the “Parent Releasing Parties”) hereby irrevocably
and unconditionally releases and forever discharges each Released Seller, including their respective subsidiaries, affiliates,
predecessors, successors, and assigns, and each of its respective past, present, and future officers, directors, security holders,
partners, agents, representatives, employees, advisors, attorneys, and all Persons acting by, through, for, under, or in concert
with any of the foregoing (collectively, the “Released Seller Parties”), from any and all Proceedings, damages,
costs, expenses, demands, debts, liabilities and obligations, whether known or unknown, primary or secondary, direct or indirect,
and whether or not accrued (“Claims”), which any Parent Releasing Party now has or ever had from the beginning
of time up to and including the Effective Date against any of the Released Seller Parties, arising from any acts or omissions,
state of facts or circumstances, or events which occurred, existed or were suffered to exist from the beginning of time through
and including the Effective Date, in each case, other than: (i) all rights and obligations of the Rising Buyer under the Rising
Purchase Agreement or any Ancillary Document (as defined in the Rising Purchase Agreement); (ii) Claims arising from any criminal
or administrative Proceeding brought by or in the right of any Governmental Authority, including, without limitation, any violation,
or alleged violation, of Competition Laws (except for the “TAA Matter” as defined in the indemnification notices sent
by one or more Parent Parties pursuant to the Product Purchase Agreement, which TAA Matter shall be a Parent Released Claim that
is released by this Mutual Release); and (iii) this Mutual Release (collectively, the “Parent Released Claims”).
Notwithstanding the foregoing, nothing in this paragraph shall inhibit the Parent Parties from asserting any defenses or set-off
rights to claims asserted by the Released Seller Parties with respect to Claims released hereunder, which defenses and set-off
rights are expressly preserved.

 

    	 	-2-	 

     

    

 

		b.	Each Parent Party hereby irrevocably covenants, from and after the Effective Date, to refrain from
asserting any claim or demand, or commencing, instituting or causing to be commenced, any Proceeding against any of the Released
Seller Parties based upon, arising from or relating to any Parent Released Claim or any Claim described in Section 1.a(ii),
subject only to the terms of this Mutual Release.

 

		c.	Effective as of the Effective Date and only if the Effective Date occurs, each of the Released
Seller Parties (collectively, the “Releasing Seller Parties”) hereby irrevocably and unconditionally releases
and forever discharges each Parent Releasing Party (collectively, the “Released Parent Parties”), from any and
all Claims, which any Releasing Seller Parties now has or ever had from the beginning of time up to and including the Effective
Date against any of the Released Parent Parties, arising from any acts or omissions, state of facts or circumstances, or events
which occurred, existed or were suffered to exist from the beginning of time through and including the Effective Date, in each
case, other than: (i) all rights and obligations of each Released Seller Party under the Rising Purchase Agreement or any Ancillary
Document (as defined in the Rising Purchase Agreement); (ii) all rights and obligations of a Parent Party for payment to any Released
Seller in respect of (A) the Deferred Payment Amount (less the Release-Related DPA Reduction and, if credited towards Purchase
Price (as defined in the Rising Purchase Agreement) upon Closing (as defined in the Rising Purchase Agreement), the Deferred Payment
Reduction (as defined in the Rising Purchase Agreement), (B) interest in respect of the Deferred Payment Amount (less the Interest
Credit and, if credited towards Purchase Price (as defined in the Rising Purchase Agreement) upon Closing (as defined in the Rising
Purchase Agreement), the amount of the Seller Credit (as defined in the Rising Purchase Agreement) allocable to such interest payment),
(C) if an Alternative Transaction (as defined in the Rising Purchase Agreement) is consummated or upon the occurrence of the events
described in Section 1.f(y)(iii) (1) Earn-Out Payments (unless the Earn-Out Products are acquired by the Rising Buyer upon
Closing), and (2) the Administration Services Agreement, and (D) the Equity Consideration; (iii) in the case of Kavuru, any rights
and obligations of each Parent Party to provide coverage and indemnification to Kavuru pursuant to any director and officer insurance
or indemnification obligations in respect of his position as a director or an officer of any Parent Party, in each case, as in
effect on the date hereof; and (iv) this Mutual Release (collectively, the “Seller Released Claims”). Notwithstanding
the foregoing, nothing in this paragraph shall inhibit the Released Sellers from asserting any defenses or set-off rights to claims
asserted by the Released Parent Parties with respect to Claims released hereunder, which defenses and set-off rights are expressly
preserved. The interest accrual on the Deferred Payment Amount shall be calculated only on the outstanding amounts after giving
effect to the reductions described herein and in the Rising Purchase Agreement.

 

    	 	-3-	 

     

    

 

		d.	Each Released Seller hereby irrevocably covenants, from and after the Effective Date, to refrain
from asserting any claim or demand, or commencing, instituting or causing to be commenced, any Proceeding against any of the Released
Parent Parties based upon, arising from or relating to any Seller Released Claims.

 

		e.	Notwithstanding anything in this Mutual Release to the contrary, if any Released Seller Party or
Released Parent Party is found by a court of competent jurisdiction in a final non-appealable order to have breached this Mutual
Release, then this Mutual Release shall thereupon, without further action, notice or deed, be void ab initio with respect
to such Released Seller Party or Released Parent Party.

 

		f.	The “Effective Date” shall mean the later of (x) the date on which the Bankruptcy
Court approves this Mutual Release by Final Order (as defined in the Rising Purchase Agreement) and (y) the earliest of: (i) the
Closing (as defined in the Rising Purchase Agreement); (ii) consummation of an Alternative Transaction (as defined in the Rising
Purchase Agreement) in accordance with Section 8.1(h) of the Rising Purchase Agreement; or (iii) if (A) all of the conditions set
forth in Sections 7.1 and 7.2 of the Rising Purchase Agreement to the Rising Sellers’ obligations thereunder are satisfied
(other than those conditions that by their nature are to be satisfied at such Closing, provided, that such conditions would
have been satisfied assuming such Closing were to occur), (B) the Rising Buyer has irrevocably confirmed in writing to the Rising
Sellers that (1) all of the conditions set forth in Sections 7.1 and 7.3 of the Rising Purchase Agreement to the Rising Buyer’s
obligations thereunder have been satisfied or waived (other than those conditions that by their nature are to be satisfied or waived
at such Closing, provided, that such conditions would have been satisfied or waived assuming such Closing were to occur),
and (2) it is ready, willing and able to take the actions within its control to consummate such Closing in accordance with the
Rising Purchase Agreement, without further condition, and (C) the Rising Sellers fail to consummate such Closing, on the terms
and subject to the conditions set forth in the Rising Purchase Agreement, within three (3) Business Days following receipt of the
written confirmation by the Rising Buyer required by clause (iii)(B) of this Section 1.f. If the Rising Purchase Agreement
shall have terminated in accordance with its terms before the occurrence of the Effective Date or any of the Rising Sellers shall
have commenced an action for specific performance pursuant to Article VIII of the Rising Purchase Agreement, then this Mutual Release
shall, thereon, without further action, notice or deed, terminate and be void ab initio.

 

    	 	-4-	 

     

    

 

		g.	General Release.   Subject only to the terms of this Mutual Release, the Parties
and each of them, agree to and hereby does release and discharge the Parent Released Parties and the Seller Released Parties (as
the case may be) from the Claims in Section 1(a) and Section 1(c), which are based on acts or omissions occurring
up to and including the Effective Date.  The Parties understand and expressly agree that all rights under Section 1542 of
the California Civil Code, if any, are hereby expressly waived. That Section reads as follows:

 

"A general release does
not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release,
which if known by him or her must have materially affected his or her settlement with the debtor."

 

The waiver of Section 1542 provided
by this Section 1(f) is an essential term of this Mutual Release without which the settlement would not have been reached.

 

		2.	Disclaimer of Reliance. In executing the releases set forth in Section 1 above, the
Parties intend this instrument to be effective as a full and final accord and satisfaction of the Parent Released Claims and the
Seller Released Claims. Each Party expressly warrants and represents that no promise or agreement that is not expressed in this
Mutual Release has been made to such Party as an inducement to execute this Mutual Release and each Party expressly disclaims reliance
upon any statement or representation of any Person or entity released hereby other than those expressly stated in this Mutual Release.
In entering into this Mutual Release, the Parties each expressly disclaim and waive any reliance on any written or oral representations,
other than those expressly stated herein.

 

		3.	Miscellaneous.

 

		a.	Representations and Warranties. Each Party hereby represents and warrants to the other Parties
that (i) such Party has had the opportunity to review this Mutual Release with counsel, (ii) such Party has been fully advised
as to the terms herein and fully appreciates and understands such terms, (iii) such Party has all requisite power and authority
to execute and deliver this and to perform his, her or its obligations hereunder, except, with respect to the Parent Parties, such
power and authority is subject to approval of the Bankruptcy Court by Final Order (as defined in the Rising Purchase Agreement),
and (iv) this Mutual Release has been duly and validly executed and delivered by such Party and, assuming the valid execution and
delivery by the other Parties, constitutes a valid and binding agreement of such Party enforceable against such Party in accordance
with its terms, except as the same may be limited by bankruptcy, insolvency, reorganization, moratorium or similar laws now or
hereafter in effect relating to creditors’ rights generally and subject to general principles of equity (except, with respect
to the Parent Parties, subject to approval of the Bankruptcy Court by Final Order (as defined in the Rising Purchase Agreement)).

 

    	 	-5-	 

     

    

 

		b.	No Admission of Liability. The execution of this Mutual Release and the fulfillment of its
terms is a compromise of disputed claims and is not to be construed as, and does not constitute, an admission of liability or wrongdoing
or responsibility on the part of any Party, and the material purpose of the actions taken hereunder are solely for the purpose
of avoiding the expense and time of litigation.

 

		c.	Amendment. No provision or term hereof may be amended, supplemented, or otherwise modified
except by an instrument in writing, specifying the same, duly executed by each of the Parties.

 

		d.	Assigns. The Parties shall not assign any rights or obligations hereunder without the written
consent of all other Parties.

 

		e.	Heading References. The heading references herein are for convenience purposes only, do
not constitute a part of this Mutual Release, and shall not be deemed to limit or affect any of the provisions hereof.

 

		f.	Severability. Should any portion of this Mutual Release be held invalid by operation of
law or by a court with proper jurisdiction, the remaining portion of this Mutual Release shall be given full force and effect and
shall not in any way be affected thereby.

 

		g.	Entire Agreement. This Mutual Release, the Rising Purchase Agreement and the Transaction
Agreements represent the entire understanding and agreement among the Parties with respect to the subject matter hereof, and supersede
all prior agreements, if any, among them with respect thereto. In the event of any conflict or inconsistency between the provisions
of this Mutual Release and the provisions of the Product Purchase Agreement, the provisions of this Mutual Release shall control.

 

		h.	Counterparts. This Mutual Release may be executed in one or more counterparts (including
by facsimile or electronic .pdf submission), each of which shall be deemed an original, and all of which shall constitute one and
the same agreement and shall become effective when one or more counterparts have been signed by each of the Parties and delivered
(by telecopy, portable document format (.pdf) or otherwise) to the other Parties, it being understood that all Parties need not
sign the same counterpart.

 

		i.	Governing Law. This Mutual Release shall be construed and enforced in accordance with the
laws of the State of New York, without regard to any conflict of laws provisions thereof that would result in the application of
the laws of any other jurisdiction.

 

		j.	Submission to Jurisdiction. Each Party hereto hereby irrevocably and unconditionally: (i)
consents and submits for itself and its property in any Proceeding based upon, arising out of, or related to this Mutual Release
or its negotiation, execution, performance, non-performance, interpretation, termination, construction or the transactions contemplated
hereby, or for recognition and enforcement of any judgment in respect thereof, to the exclusive jurisdiction of the Bankruptcy
Court; (ii) consents that any such Proceeding may be brought in such court, and waives any objection that it may now or hereafter
have to the venue of any such Proceeding in any such court or that such Proceeding was brought in an inconvenient court and agrees
not to plead or claim the same; (iii) agrees that service of process in any such Proceeding may be effected by mailing a copy thereof
by registered or certified mail (or any substantially similar form of mail), postage prepaid, to any Party at its, his or her address
set forth in Section 3(o) of this Mutual Release; and (iv) agrees that nothing herein shall affect the right to effect service
of process in any other manner permitted by Law. Each of the Parties also agrees that any final, non-appealable judgment against
a Party in connection with any Proceeding arising out of or relating to this Mutual Release may be enforced in any court of competent
jurisdiction, either within or outside of the United States.

 

    	 	-6-	 

     

    

 

		k.	WAIVER OF JURY TRIAL: TO THE FULLEST EXTENT PERMITTED BY LAW, THE PARTIES HEREBY WAIVE THEIR
RESPECTIVE RIGHTS TO A JURY TRIAL OF ANY PROCEEDING BASED UPON, ARISING OUT OF, OR RELATED TO THIS MUTUAL RELEASE, OR ANY OF THE
TRANSACTIONS CONTEMPLATED BY THIS MUTUAL RELEASE. THE SCOPE OF THIS WAIVER IS INTENDED TO BE ALL-ENCOMPASSING OF ANY AND ALL DISPUTES
THAT MAY BE FILED IN ANY COURT AND THAT RELATE TO THE SUBJECT MATTER OF THIS MUTUAL RELEASE, INCLUDING CONTRACT CLAIMS, TORT CLAIMS,
BREACH OF DUTY CLAIMS AND ALL OTHER COMMON LAW AND STATUTORY CLAIMS. THE PARTIES ACKNOWLEDGE THAT THIS WAIVER IS A MATERIAL INDUCEMENT
TO ENTER INTO A BUSINESS RELATIONSHIP, THAT EACH HAS ALREADY RELIED ON THIS WAIVER IN ENTERING INTO THIS MUTUAL RELEASE AND THAT
EACH WILL CONTINUE TO RELY ON THE WAIVER IN THEIR RELATED FUTURE DEALINGS. THE PARTIES FURTHER WARRANT AND REPRESENT THAT EACH
HAS REVIEWED THIS WAIVER WITH ITS LEGAL COUNSEL, AND THAT EACH KNOWINGLY AND VOLUNTARILY WAIVES ITS JURY TRIAL RIGHTS FOLLOWING
CONSULTATION WITH LEGAL COUNSEL. THIS WAIVER IS IRREVOCABLE, MEANING THAT IT MAY NOT BE MODIFIED EITHER ORALLY OR IN WRITING, AND
THIS WAIVER SHALL APPLY TO ANY SUBSEQUENT AMENDMENTS, RENEWALS, SUPPLEMENTS OR MODIFICATIONS TO THIS MUTUAL RELEASE OR TO ANY OTHER
DOCUMENTS OR AGREEMENTS RELATING TO THE TRANSACTIONS CONTEMPLATED HEREBY. IN THE EVENT OF LITIGATION, THIS MUTUAL RELEASE MAY BE
FILED AS A WRITTEN CONSENT TO A TRIAL BY THE COURT.

 

		l.	Waiver. Any provision hereof may be waived only by written instrument making specific reference
to this Mutual Release signed by the Party against whom enforcement of any such waiver is sought. The waiver by any Party hereto
of a breach of any provision of this Mutual Release shall not operate or be construed as a further or continuing waiver of such
breach or as a waiver of any other or subsequent breach. No failure on the part of any Party to exercise, and no delay in exercising,
any right, power or remedy hereunder shall operate as a waiver thereof, nor shall any single or partial exercise of such right,
power or remedy by such Party preclude any other or further exercise thereof or the exercise of any other right, power or remedy.

 

    	 	-7-	 

     

    

 

		m.	Interpretation. Whenever the words “include”, “includes” or “including”
are used in this Mutual Release, they shall be deemed to be followed by the words “without limitation.” References
to sections are to sections in this Mutual Release and in each case include references to all subsections under the referenced
section. The words “hereof,” “herein” and “hereunder” and words of similar import shall refer
to all applicable provisions of this Mutual Release and not to any particular provision. This Mutual Release is the result of negotiation
and, accordingly, no presumption or burden of proof will arise with respect to any ambiguity or question of intent concerning this
Mutual Release favoring or disfavoring any Party by virtue of the authorship of any provision of this Mutual Release. Words denoting
the singular tense or person shall include the plural and vice versa and references to the masculine gender shall, where the context
permits, include the feminine and/or neuter genders and vice versa.

 

		n.	Third Party Beneficiaries. Except for the Released Parent Parties and the Released Seller
Parties who are not signatories hereto, each of whom shall be an express intended third party beneficiary hereof, there are no
third party beneficiaries, express or implied, of this Mutual Release.

 

		o.	Notices. All notices or other communications hereunder shall be deemed to have been duly
given and effective upon delivery if in writing and if served by personal delivery upon the Party for whom it is intended, if delivered
by registered or certified mail, return receipt requested, or by a national courier service, or if sent by facsimile or electronic
mail; provided, that the facsimile or electronic mail is promptly confirmed by telephone confirmation thereof or followed
by one of the other foregoing permitted means of notice (other than facsimile or electronic mail), to the Person at the address
set forth below, or such other address as may be designated in writing hereafter, in the same manner, by such Person:

 

If to any Parent Party:

 

Aceto Corporation

4 Tri Harbor Ct.

Port Washington, NY 11050

Attn: Steven S. Rogers, Chief
Legal Officer

Facsimile No.: (516) 478-9857

Email: srogers@aceto.com

 

with a copy to:

 

Lowenstein Sandler LLP

1251 Avenue of the Americas

New York, NY 10020

Attn: Steven E. Siesser, Esq.

Facsimile No.: (973) 597-2507

Email: ssiesser@lowenstein.com

 

If to any Released Seller:

 

Vimal Kavuru, Agent

[   ]

 

with a copy to (which shall not
constitute notice):

 

Reed Smith LLP

599 Lexington Avenue

Attention: Niket Rele, Esq.

E-mail: nrele@reedsmith.com

 

[Remainder of page
intentionally left blank. Signatures follow.]

 

    	 	-8-	 

     

    

 

IN WITNESS WHEREOF,
each of the undersigned has executed this Mutual Release effective as of the Effective Date.

 

	ACETO CORPORATION 	 
	 	 	 
	By:	 /s/ William C. Kennally, III                 	 
	 	Name: William C. Kennally, III	 
	 	Title: Chief Executive Officer and President	 
	 	 	 
	RISING PHARMACEUTICALS, INC. 	 
	 	 	 
	By:	/s/ William C. Kennally, III	 
	 	Name: William C. Kennally, III	 
	 	Title: Chief Executive Officer	 
	 	 	 
	ACETRIS HEALTH, LLC	 
	 	 	 
	By:	/s/ William C. Kennally, III	 
	 	Name: William C. Kennally, III	 
	 	Title: Chief Executive Officer	 
	 	 	 
	RISING HEALTH, LLC	 
	 	 	 
	By:	/s/ William C. Kennally, III	 
	 	Name: William C. Kennally, III	 
	 	Title: Chief Executive Officer	 

 

[Signature page to Mutual Release]

 

    	 	 	 

     

    

 

	sHORE PHARMA LLC	 
	 	 	 
	By:	/s/ Vimal Kavuru	 
	 	Name:  Vimal Kavuru	 
	 	Title: Sole Member	 
	 	 	 
	Cedar Pharma LLC	 
	 	 	 
	By:	/s/ Vimal Kavuru	 
	 	Name: Vimal Kavuru	 
	 	Title: Manager and CEO	 
	 	 	 
	Aster pharma LLC	 
	 	 	 
	By:	/s/ Vimal Kavuru	 
	 	Name: Vimal Kavuru	 
	 	Title: Manager and CEO	 
	 	 	 
	CITGEN PHARMA HOLDING LLC	 
	 	 	 
	By:	/s/ Vimal Kavuru	 
	 	Name:  Vimal Kavuru	 
	 	Title: Manager	 
	 	 	 
	GENSOURCE PHARMA LLC	 
	 	 	 
	By:	/s/ Vimal Kavuru	 
	 	Name:  Vimal Kavuru	 
	 	Title: Manager	 
	 	 	 
	SS PHARMA LLC	 
	 	 	 
	By:	/s/ Subha Sri Thogarchedu	 
	 	Name:  Subha Sri Thogarchedu	 
	 	Title: Sole Member	 

[Signature page to Mutual Release]

    	 	 	 

     

    

 

	PHARMA REACH LLC	 
	 	 	 
	By:	/s/ Subha Sri Thogarchedu	 
	 	Name:  Subha Sri Thogarchedu	 
	 	Title: Sole Member	 
	 	 	 
	CITGEN PHARMA LLC	 
	 	 	 
	By:	/s/ Vimal Kavuru	 
	 	Name:  Vimal Kavuru	 
	 	Title: Manager	 

 

	/s/ Sudha Kavuru 	 
	Sudha Kavuru, individually	 
	 	 
	/s/ Vimal Kavuru	 
	Vimal Kavuru, individually	 
	 	 
	/s/ Subha Sri Thogarchedu 	 
	Subha Sri Thogarchedu, individually	 

 

[Signature page to Mutual Release]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00293-of-00352.parquet"}]]